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Review of Drug Quality and Security Act of 2013:  The Drug Supply Chain Security Act (DSCSA) 
Elona Gjini, PharmD candidate 2017 and Albert Wertheimer, PhD 
Temple University School of Pharmacy 
 
In November 15, 2012, Dr. Margaret Hamburg a 
Commissioner of Food Drug Administration (FDA) testified 
before Congress regarding the tragic fungal meningitis 
outbreak associated with compounded methylprednisolone 
acetate, a steroid injectable product distributed by the New 
England Compounding Center in Framingham, Massachusetts 
that led to the death of 64 people.1 A year later, in November 
27, 2013 President Obama signed into law the Drug Quality 
and Security Act (DQSA). Title 1 of DQSA addresses 
compounding provisions through the Compounding Quality 
Act (CQA) which was motivated by the Framingham tragedy. 2 
The Drug Supply Chain Security Act (DSCSA) is one of the two 
titles that comprises DQSA and it creates a uniform, national 
standard for tracing drug products through the supply chain. 
The goal of DQSA is to enhance FDA’s ability to help protect 
consumers by detecting and removing potential dangerous 
products from the pharmaceutics distribution supply chain. 
DQSA outlines all the steps of a new electronic, interoperable 
system that will identify and trace certain prescription 
medication while distributed in the United States. The 
development of this system will be phased in with specific 
requirements over a 10 year period. It will be a cooperation 
between FDA and drug manufactures, wholesale drug 
distributors, repackagers and dispensers (primarily 
pharmacies).3 Table 1. outlines all the services that the 
DQSA’s new system will provide. 
 
The implementation of the DSCSA is based on several law 
requirements and FDA has developed a schedule with time 
frames for each of them to be executed over a 10 year 
period. There are 15 key activities of the FDA plan that will 
guarantee an efficient and effective implementation 
described in table 2.4 
 
Moreover, there are certain key provisions of the DSCSA 
which will be implemented over the next 10 years that 
require:  
 
I. Product identification: Manufacturers and repackagers 
to put a unique product identifier on certain prescription 
drug packages, for example, using a bar code that can be 
easily read electronically. 
II. Product tracing: Manufacturers, wholesaler drug 
distributors, repackagers, and many dispensers (primarily 
pharmacies) in the drug supply chain to provide 
information about a drug and who handled it each time it 
is sold in the U.S. market. 
III. Product verification: Manufacturers, wholesaler drug 
distributors, repackagers, and many dispensers (primarily 
pharmacies) to establish systems and processes to be 
able to verify the product identifier on certain 
prescription drug packages. 
IV. Detection and response: Manufacturers, wholesaler 
drug distributors, repackagers, and many dispensers 
(primarily pharmacies) to quarantine and promptly 
investigate a drug that has been identified as suspect, 
meaning that it may be counterfeit, unapproved, or 
potentially dangerous. 
V. Notification: Manufacturers, wholesaler drug 
distributors, repackagers, and many dispensers (primarily 
pharmacies) to establish systems and processes to notify 
FDA and other stakeholders if an illegitimate drug is 
found. 
VI. Wholesaler licensing: Wholesale drug distributors to 
report their licensing status and contact information to 
FDA. This information will then be made available in a 
public database. 
VII. Third-party logistics provider licensing: Third-party 
logistic providers, those who provide storage and 
logistical operations related to drug distribution, to 
obtain a state or federal license. 2 
 
In order to understand FDA requirements for the authorized 
trading partners, such as manufacturers, wholesaler drug 
distributors, repackagers, and dispensers it is important to 
understand the DSCSA definition for each of them. Under the 
DSCSA: 
 
I. Manufacturer is a person that holds an application 
approved under section 505 or a license issued under 
section 351 of the Public Health Service Act for such 
product; if such product is not the subject of an approved 
application or license, the manufacturer is defined as the 
person who manufactured the product, a co-licensed 
partner that obtains the product directly, or an affiliate. 
 
II. Wholesale distributor is a person (other than the 
manufacturer, a manufacturer’s co-licensed partner, a 
third party logistics provider or repackager) who is 
engaged in the wholesale distribution. Whole sale 
distribution is the distribution of a prescription product 
to an entity or person other than the patient. 
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III. Dispenser is an entity that is authorized to dispense or 
administer prescription drugs and the affiliated 
warehouses or distribution centers of such entities: 
 
o A retail pharmacy 
o A hospital pharmacy 
o A group of chain pharmacies that does not act 
as a wholesale distributor  
o Any other person authorized by the law  to 
dispense or administer prescription drugs 
o Affiliated warehouses or distribution centers of 
such entities under common control  that do not 
act as a wholesale distributor2 
In addition, the DSCSA implementation plan includes some 
important dates for the authorized partners requirements 
described in the Table 3.4 
 
The DSCSA traceability process includes only prescription 
drugs in the finished form for human use. There are certain 
products that are excluded from the DSCSA list. Table 4 
includes all these products. 5 
 
Product tracking and tracing requirements are two important 
features of DSCSA. Transaction records as a part of DSCSA 
includes 3 components: transaction history (HI), transaction 
information (TI) and transaction statement (TS).5 
TI must include: 
 
• Proprietary or established name or names of the 
product 
• Strength and dosage form of the product 
• National Drug Code (NDC) of the product 
• Container size 
• Number of containers  
• Lot number of the product 
• Date of the shipment, if more than 24 hours after 
the date of transaction 
• Business name and address of the person from 
whom and to whom ownership is being transferred 
All sellers must provide the TI, TH, and TS to the subsequent 
owner for each transaction and each buyer must store the 
information received. All trading partners must store the 
records for a period of 6 years and make them available to a 
FDA audit.2 Most of the data is stored through web-based 
portals. There are some changes regarding the dispenser 
(primarily pharmacies) where the lot number, transaction 
date and shipment date are required only if the pharmacy 
purchase a product from a second distributor instead of the 
primary distributor that buys directly from a manufacturer. In 
addition, the dispenser can return saleable products or non-
saleable products to the trading partners without providing 
the requisite information; however by 2019 wholesale 
distributors will accept return products only if they contain 
the required product identifier.2 
 
Tracing exceptions comprises another important feature of 
the DSCSA that are presented as following: 
 
• Intracompany distribution of any product 
between members of an affiliate or within a 
manufacturer 
• Distribution of product between hospitals or 
health care entities under common control 
• Distribution of product for emergency 
medical reasons, which includes a public 
health emergency and excludes a drug 
shortage, unless caused by such a public 
health emergency 
• Distribution of minimal quantities by a 
licensed retail pharmacy or licensed 
practitioner for office use. (“Minimal 
quantities” is not defined by the DSCSA, but 
many states define this as 5% or less of a 
pharmacy’s sales. Pharmacists and pharmacy 
technicians should check with their state 
boards of pharmacy or appropriate 
regulatory bodies to verify the definition of 
“minimal quantities”) 
• Dispensing pursuant to a prescription 
• Pharmacy sale to another pharmacy for a 
“specific patient need.” A specific patient 
need means that an identified patient exists; 
it does not include transfers for the purpose 
of increasing or replenishing the quantity of a 
product in anticipation of a potential need2 
 
In order to help trading partners, FDA has issued a document, 
FDA Guidance on Identifying Suspect Product and Notification 
that provides information about the risk of suspect drugs 
entering the supply chain. Some example scenarios include 
product sourcing, supply, demand, history, and value of the 
product, and product appearance. When dealing with 
product sourcing trading partners should be careful when 
they purchase from a new and unknown source, receive 
products from an unknown source, or purchasing from a 
trading partner who is involved in selling or delivering 
illegitimate products. In addition, the trading partner has a 
history of potentially false transaction histories (misspelled 
words or incomplete information), is reluctant to provide TH, 
or a TI, TS, and /or TH appears to be suspicious. Another 
scenario provided in the FDA guidance document is related to 
supply, demand, history, and value of the product. They 
include products that are in high demand, have a high sales 
volume, and have been previously counterfeited. Also, 
products that have been or are currently the subject of drug 
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shortage, have been subject of illegitimate product 
notification, and have been the subject of an FDA counterfeit 
or cargo theft alert. The last FDA example scenario 
recommends additional caution to a product appearance. 
Suspicious appearance includes: a transport container with a 
non-standard label (color, font, images), drug identification 
number that is different from NDC, missing information (lot 
number or expiration date), missing counterfeit technologies 
(holograms, color shifting inks, or watermarks), and a finished 
product that has different shape or color, unusual imprint or 
odor, and chips or cracks in the tablet coatings.6  
 
The scenarios described above should not be view as an 
exhaustive list of all potential scenarios, but pharmacists and 
pharmacy technicians can use them to identify suspect 
products being delivered to their pharmacy. Accessing the 
DSCSA online resources on the FDA website is another way 
for dispensers to be up-to date with the implementation plan 
requirements. 
 
Implementing the DSCSA law requirements is a challenging 
and complicated process. In order to receive valuable 
feedback from stakeholders, FDA held a public workshop on 
“Proposed Pilot Project under the Drug Supply Chain Security 
Act” in Silver Spring, MD, on April 5-6, 2016. Many 
participants including drug manufacturers, repackagers, 
wholesale distributors, third-party logistics providers, 
dispensers (pharmacies), and consultants shared their input 
related to the product identifiers, barcodes, interoperability, 
aggregation, database issues, and verification and notification 
issues. Moreover, the implementation of DSCSA 
requirements are not cheap, some of them include costs of 
$150-300,000 per packaging line and installation of IT 
systems to store and transmit data just to name a few.2 I 
believe that a unified system will provide easier data 
exchange and fewer errors, will increase the safety and 
security of the pharmaceutical distribution supply chain. In 
addition, it will improve the supply-demand balance, allow 
better control of inventory, facilitate easier returns and 
recalls, decrease drug diversion and uncontrolled pricing. 
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Table 1.  DQSA national system services 
                              DQSA National Electronic System   
Enable verification of the legitimacy of the drug product identifier down to the package level 
 
Enhance detection and notification of illegitimate products in the drug supply chain 
 
Facilitate more efficient recalls of drug products 
 
 
Table 2. DSCSA implementation plan 
Activities Planned FDA Implementation Period Planned Stakeholder 
Implementation Period 
Issue notice of public docket to collect stakeholder 
comments on standards for interoperable exchange 
of transaction information, history and statement in 
paper or electronic format 
Beginning of 2014 through early 2014  
Publish guidance on identification of suspect product 
and termination of notifications of illegitimate 
product for finished human prescription drugs 
Beginning of 2014 through mid-2014  
Publish draft guidance establishing standards for 
interoperable exchange of transaction information, 
history, statement in paper or electronic format 
Beginning of 2014 through late 2014  
Establish a system for third-party logistic provider 
reporting to FDA 
Beginning of 2014 through late 2014  
Establish a system for wholesale drug distributor 
reporting to FDA and public database with licensing 
information. 
Beginning of 2014 through late 2014  
Establish a system for wholesale drug distributor 
reporting to FDA and public database with licensing 
information 
Beginning of 2014 through the end of 
2014 
 
Develop regulations establishing standards for 
licensing of wholesale drug distributors.  
Beginning of 2014 through late 2015 Late 2015 through late 2017 
Develop regulations establishing standards for 
licensing of third-party logistics providers 
Beginning of 2014 through late 2015  Late 2015 through late 2016 
Publish guidance on processes for waivers, 
exceptions, exemptions 
Beginning of 2014 through late 2015 Late 2015 through mid-2017 
Publish final guidance on grandfathering product Beginning of 2014 through late 2015.  
Conduct at least five public meeting Beginning of 2015 through mid-2021  
Establish one or more pilot projects in coordination 
with stakeholders to explore and evaluate methods 
to enhance the safety and security of supply chain 
Beginning of 2015 through end of 2020  
Conduct and complete a technology and software 
assessment on feasibility of small dispensers to 
conduct drug tracing at the package level. 
Beginning of 2017 through end of 2020  
Publish final guidance on system attributes necessary 
to enable secure tracing at the package level 
Beginning of 2018 through late-2022 Late 2022 through late 2023 
Publish final guidance on the standards for 
interoperable data exchange to enhance secure 
tracing of product at package level 
Beginning of 2018 through late-2022  Late 2022 through late 2023 
Develop regulations establishing enhanced drug 
distribution security system for interoperable 
electronic tracing of product at the package level 
Beginning of 2017 through late-2021 Late 2021 through late 2023 
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Table 3. DSCSA key dates for partners 
Authorized Partners  Action Required Dates 
Manufactures and distributors Send and receive tracking and tracing 
documents. Suspect and illegitimate 
products requirements became 
effective 
January 1, 2015 
Dispensers Receive tracking and tracing 
documentation, capture information, 
and maintain documentation for 6 
years  
July 1, 2015 
FDA Establish national standards for 
tracking , and tracing documentation 
in paper and electronic format, and 
waivers, exceptions, exemptions, and 
grandfathered guidance 
November 27, 2015 
Manufacturers  All product must be serialized November 27, 2017 
Repackagers All product must be serialized November 27, 2018 
Wholesalers Engage only in transactions with 
serialized products 
November 27, 2019 
Dispensers Engage only in transactions with 
serialized products, and pharmacy lot-
level traceability is required  
November 27, 2020 
All Unit-level traceability required November 27, 2023 
 
 
 
Table 4. Products not included in the DSCSA 
Products excluded from DSCSA list 
Over the counter medications Compounded drugs  
Blood or blood components for transfusion Dialysis solutions 
Radioactive drugs or radioactive biological products Sterile water (irrigation or injectable), IV products 
intended for replenishment of fluids and electrolytes 
(sodium, chloride, potassium, etc.) or calories (dextrose, 
amino acids, lipids) 
Imaging drugs Combination kits or trays that do not include a 
controlled substance, i.e., first aid kits, suture kits 
Medical gases Drug samples 
Drug samples  Minimal quantities of product from a licensed retail 
pharmacy to a licensed practitioner for office use  
Distribution between facilities under common 
ownership 
Dispensing or administering the product to the patient 
Distribution to another dispenser for a specific patient 
need 
 
  
